Consistently, the clinical relevance of CCNI2 in the human pancreatic cancer was verified through a Kaplan–Meier survival analysis, suggesting that higher expression of CCNI2 is indicative of a worse prognosis (P ═ 0.011) (Figure 1E). Here, CCNI2 is linked to familial pancreatic carcinoma.